Deep Brain Stimulation Effects on Thinking and Mood in Parkinson's Disease
Compares left and right brain stimulation effects on thinking and mood in Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Impact of Subthalamic Nucleus Deep Brain Stimulation on COGnitive and PSYchiatric Symptoms in Parkinson's Disease
Key facts
- Where
- Bern, SwitzerlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07777419, who can take part
Where in Switzerland
- University Hospital Inselspital, BerneBern, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Trial code
- NCT07777419
- Record updated
- 4 September 2026
- Original description
With this study, the investigators want to investigate how deep brain stimulation (DBS) affects various cognitive and psychiatric symptoms of Parkinson's disease (PD). In particular, they will examine whether stimulation of the left hemisphere has a different effect than stimulation of the right hemisphere on cognitive and psychiatric symptoms.Read full original descriptionShow less
Impact of Subthalamic Nucleus Deep Brain Stimulation on COGnitive and PSYchiatric Symptoms in Parkinson's Disease
With this study, the investigators want to investigate how deep brain stimulation (DBS) affects various cognitive and psychiatric symptoms of Parkinson's disease (PD). In particular, they will examine whether stimulation of the left hemisphere has a different effect than stimulation of the right hemisphere on cognitive and psychiatric symptoms.
Inclusion: Diagnosed with Parkinson's disease; Treated with subthalamic nucleus deep brain stimulation (STN-DBS); For part I: General research consent for the analysis of routine clinical data; For part II of the study: ability to provide informed consent; native German or French speaker; Montreal Cognitive Assessment with score ≥ 20.
Exclusion: Other disease affecting the brain (e.g. Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, non-provoked epilepsy, brain tumour, etc.); Haemorrhage during implantation of STN-DBS, which resulted in permanent cognitive or physical impairment; Schizophrenia, ongoing substance abuse, bipolar disorder or autism; For part II: Severe depressive disorder and/or suicidality; Atypical Parkinsonism; Insufficient quality or lack of brain imaging data pre and/or post STN-DBS.